A study published in Diabetes, Metabolic Syndrome and Obesity evaluated the antioxidant effect of rosuvastatin in diabetic polyneuropathy. This randomized, double-blind, placebo-controlled Phase IIa clinical trial of patients with type-2 diabetes and diabetic polyneuropathy (DPN) stage ≥1b allocated subjects to two parallel groups, in the ratio 1:1. The first group received rosuvastatin 20 mg for 12 weeks, whereas the second group was given a placebo for the same duration. Both groups were of similar age and time-lapses since diagnosis of diabetes and DPN. It was observed that DPN improved in the rosuvastatin group from stage-2a to stage-1b; while neuropathic symptom score improved from 4.5±2 to 2.4±1.8. Furthermore, significant reductions of peroneal nerve conduction velocity and lipid peroxidation were observed. Thus, it was concluded that the severity, symptoms, and nerve conduction parameters of DPN improved after a 12-week rosuvastatin therapy. It was stated that these beneficial effects appear to be attributable to reductions in lipid peroxidation and oxidative stress.